Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ: FGEN )

0.4271 -0.0029 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
Qiming, a prominent China-based venture capital firm, has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial... 
Via Talk Markets
FibroGen Out-Licenses Recombinant Human Collagen-Based Biosynthetic Cornea
Eluminex Biosciences (Suzhou) Limited has exclusively licensed global rights to develop and commercialize a biosynthetic cornea from FibroGen Inc (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
Exposures Product Safety
50 Biggest Movers From Friday
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 41.2% to settle at $7.10 on Friday. Blue Foundry Bancorp (NASDAQ: BLFY) gained 29% to close at $12.90 after the... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.63% to 34,766.06 while the NASDAQ fell 0.47% to 14,475.13. The S&P also fell, dropping 0.53% to 4,336.88. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why FibroGen Stock Is Plunging Today
An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns. 
Via The Motley Fool
Exposures Product Safety
Stocks Reverse Gains as Inflation Fears Weigh
Stocks reversed earlier gains brought on by strong retail sales data and mixed earnings reports, as worse-than-expected inflation findings weighed on Wall Street. 
Via Talk Markets
FibroGen Analyst Removes Roxadustat Sales From Model After AdCom Snub
FibroGen, Inc. (NASDAQ:FGEN) shares were slumping over 40%... 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers TD Holdings, Inc. (NASDAQ: GLG) jumped 49% to $1.21 after the company entered a non-binding letter of intent to acquire Guangdong Jinbochuang Special Purpose Vehicle Co.... 
Via Benzinga
Analyzing FibroGen's Unusual Options Activity
Shares of FibroGen (NASDAQ:FGEN) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $13.83. Sentiment: BEARISH Option... 
Via Benzinga
FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall
FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs. 
Via InvestorPlace
Exposures Product Safety
Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views
Following the market opening Friday, the Dow traded down 0.41% to 34,844.89 while the NASDAQ fell 0.30% to 14,499.54. The S&P also fell, dropping 0.30% to 4,346.93. The U.S.... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Why FibroGen's Stock Is Getting Hammered Today
FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to... 
Via Benzinga
Exposures Product Safety
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday. 
Via Investor's Business Daily
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE: 
Via Benzinga
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Credit Suisse raised Cintas Corporation (NASDAQ: CTAS) price target from $350 to $375. Cintas shares rose 1.4% to $374.12 in pre-market trading. Barclays raised the price target... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton... 
Via Benzinga
22 Stocks Moving in Friday's Pre-Market Session
Gainers Aehr Test Systems (NASDAQ: AEHR) shares rose 25.3% to $3.52 in pre-market trading after the company reported better-than-expected Q4 results and issued strong FY22 sales... 
Via Benzinga
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?
FibroGen, Inc.’s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen’s AdCom Snub FibroGen said late Thursday the... 
Via Benzinga
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday w... 
Via Benzinga
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions
Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.